MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
Dynatronics Corporation Cost of Revenue 2011-2026 | DYNT
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Dynatronics Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.4 M | 24.9 M | 30.5 M | 33.7 M | 34.9 M | 38.3 M | 43.4 M | 44 M | 24.2 M | 20.1 M | 20 M | 17.4 M | 18.5 M | 19.7 M | 20.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44 M | 17.4 M | 27.4 M |
Quarterly Cost of Revenue Dynatronics Corporation
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.29 M | - | 5.66 M | 5.62 M | - | 6.33 M | 7.05 M | - | 7.03 M | 7.82 M | 8.41 M | 16.2 M | 8.01 M | 8.45 M | 8.64 M | 17.1 M | 8.16 M | 8.63 M | 8.23 M | 8.63 M | 8.23 M | 10.6 M | 11.2 M | 10.6 M | 11.2 M | 10.8 M | 11.5 M | 10.8 M | 11.5 M | 12.3 M | 8.46 M | 12.3 M | 8.46 M | 5.64 M | 5.37 M | 5.64 M | 5.37 M | 4.8 M | 4.89 M | 4.8 M | 4.89 M | 4.84 M | 4.65 M | 4.84 M | 4.65 M | 4.47 M | 4.47 M | 4.47 M | 4.47 M | 4.9 M | 4.5 M | 4.9 M | 4.5 M | 5.06 M | 4.99 M | 5.06 M | 4.99 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.1 M | 4.47 M | 7.42 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
1.2 B | $ 186.15 | 3.03 % | $ 13.9 B |  USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 11.57 | 2.84 % | $ 1.74 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 34.98 | 4.51 % | $ 1.61 B | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.33 | 0.15 % | $ 125 M |  France |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 12.54 | 1.78 % | $ 1.69 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 292.47 | 1.49 % | $ 8.25 B | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.57 | -2.41 % | $ 35.5 M | USA |
 |
Inogen
INGN
|
194 M | $ 6.45 | - | $ 172 M | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 40.21 | 2.97 % | $ 5.99 K | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 64.38 | 1.9 % | $ 95.3 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.98 | 1.01 % | $ 71.5 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 10.28 | 2.7 % | $ 291 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
14 M | $ 25.14 | 0.76 % | $ 213 M | USA |
 |
Myomo
MYO
|
14 M | $ 0.75 | 3.23 % | $ 31.4 M | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 2.95 | 0.4 % | $ 8.18 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Globus Medical
GMED
|
958 M | $ 95.0 | 2.17 % | $ 12.8 B | USA |
 |
Stryker Corporation
SYK
|
9.05 B | $ 351.25 | 1.15 % | $ 134 B | USA |
 |
Tactile Systems Technology
TCMD
|
79.4 M | $ 24.87 | 2.6 % | $ 569 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.03 | - | $ 1.23 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.39 | 2.45 % | $ 929 M | USA |
 |
TransMedics Group
TMDX
|
243 M | $ 116.53 | 2.8 % | $ 3.96 B | USA |
 |
Tandem Diabetes Care
TNDM
|
469 M | $ 20.62 | 2.59 % | $ 1.4 B | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 17.45 | 2.95 % | $ 409 M | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.71 | 2.49 % | $ 384 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 55.0 | 0.15 % | $ 1.62 B | USA |